NCT04156659View on ClinicalTrials.gov

Study of Tisagenlecleucel in Chinese Pediatric and Young Adult Subjects With Relapsed or Refractory B-cell ALL

PHASE2WithdrawnINTERVENTIONAL
0
Timeline

Start Date

November 30, 2021

Primary Completion Date

November 30, 2022

Study Completion Date

November 30, 2027

Conditions
B-cell Acute Lymphoblastic Leukemia
Interventions
BIOLOGICAL

Tisagenlecleucel

A single intravenous (i.v.) infusion of CAR-positive viable T cells.

Sponsors
All Listed Sponsors
lead

Novartis Pharmaceuticals

INDUSTRY